Hematopoietic stem cell engraftment and repopulation

The phrase "Hematopoiesis restoration via engraftment/repopulation by transplanted HSCs/iPSC-derived HSPCs" does **not** refer to a single molecular target or receptor. Instead, it describes a **therapeutic process** involving the transplantation of hematopoietic stem cells (HSCs) or induced pluripotent stem cell–derived hematopoietic stem/progenitor cells (iPSC-HSPCs) to restore blood formation in patients with bone marrow failure, malignancy, immunodeficiency, or age-related decline. This process relies on the ability of transplanted cells to home to the bone marrow niche and reconstitute all blood lineages. Key challenges include ensuring long-term engraftment without lineage bias or malignant transformation—especially for iPSC-derived products that may have higher risks due to genomic instability. Conditioning regimens using chemotherapeutics like busulfan and cyclophosphamide are required prior to transplant but carry toxicity risks. Newer strategies aim at improving safety and efficacy through targeted conditioning agents and ex vivo expansion methods. Because this entry refers broadly to a therapeutic approach rather than an individual molecular entity such as a receptor or enzyme, it is **not considered a canonical drug target**, making "is_target" false and "is_incorrect" true for structured database purposes.[1][4][5]

Other names

Hematopoiesis restorationHSC engraftmentiPSC-derived HSPC transplantationhematopoietic reconstitution

Myeloablation to create space for donor cells (conditioning)[3][5] Enhancement of HSC/HSPC survival and expansion (e.g., chrysin, treprostinil/forskolin/cinacalcet combinations)[3]